The treatment of metastatic renal cell carcinoma (RCC) has changed employing the multitarget receptor tyrosine kinase (RTK) inhibitors with antiangiogenic properties ([@bib20]; [@bib26]; [@bib22]; [@bib14]), including Sunitinib, that inhibit cell signalling (including all receptors for PDGF and VEGF) leading to reduced tumour vascularisation, cancer cell death, and tumour shrinkage. The role of antiendothelial effects *vs* antitumour cells targeting *in vivo* is a matter of debate ([@bib38]; [@bib13]) regardless, no predictive markers are currently available for mRCC patients treated with this class of agents.

Circulating endothelial cell (CEC) levels were recently reported to be a pharmacodynamic biomarker of antiangiogenic treatment in combination with chemotherapy for metastatic breast cancer (MBC) ([@bib4]), but validation studies are required to further define CEC threshold for poor outcome.

Inverse correlation between circulating tumour cells (CTC) burden and overall survival in solid tumours has been reported ([@bib7]; [@bib8]; [@bib32]); variations in CTC count indicate a significant change in prognosis as early as the first treatment cycle ([@bib6]; [@bib12]; [@bib27]). Notwithstanding that 4 to 10% of RCC patients showed tumour thrombus in the inferior vena cava ([@bib19]), the occurrence of CTC was rarely investigated in these patients for correlation with an advanced tumour stage or more aggressive tumour phenotype ([@bib5]).

Recently, we have developed a CTC assay integrated for M30 neoepitope expression to monitor changes in the balance between live and apoptotic CTCs ([@bib29]) during treatment. This assay may be used as pharmacodynamic parameter disclosing an active disease, as documented by consistent radiological findings in MBC patients under chemotherapy ([@bib29]). As the antiangiogenic properties of recently approved RTKs in RCC would interfere with extravasation/circulation of CTCs ([@bib4]), we evaluated total and apoptotic CTC changes and their correlation with radiological response in a study evaluating first-line Sunitinib-treated mRCC patients. A prospective observational study was designed on the basis of the discontinuous schedule of Sunitinib administration, to monitor CTC and CEC changes during treatment intervals, when tumour evasion may occur.

Patients and methods
====================

This article has been written in accordance with the REporting of tumour MARKer studies criteria ([@bib21]).

Study design
------------

We conducted a prospective, observational study to demonstrate the association between serial total and M30-positive CTC results with disease progression in patients starting a first-line Sunitinib regimen for mRCC (Pilot Study 'Metastatic renal cancer: CTC determination in first-line Sunitinib-treated patients (CTC/Sun)\', IOV-IRCCS, Padova (Italy)); details of the study (inclusion and exclusion criteria, blood draw calendar) are on-line provided as [Supplementary Data](#sup1){ref-type="supplementary-material"}. Furthermore, we were interested in correlating the CTC detection with EpCAM expression in primary or metastatic tissue. Patient confidentiality was maintained per the policies and procedures of the IOV-IRCCS for protection from research risks. Study sponsors did not have access to the data.

Patients
--------

Between June 2008 and September 2010 peripheral blood was drawn from 53 consecutive mRCC patients (12 women and 41 men, aged 26--90 years). Whole blood was also drawn from healthy control subjects (7 women and 10 men, aged 25--76 years) who neither had known illness at the time of sampling nor history of malignant disease. All enrolled patients and healthy subjects gave their informed consent for study inclusion and were enrolled using institutional review board-approved protocols.

Forty-four patients had given their consensus to undergo multiple CTC tests for the correlation between CTC changes and treatment response; one patient lacked paired CTC results notwithstanding he had initial CTC assessments and subsequent clinical and/or radiographic documentation of disease status, so he was excluded in the analysis.

After baseline evaluation, the treating physicians conducted re-evaluations of the disease status based on Response Evaluation Criteria in Solid Tumour.

Total and M30-positive CTC and CEC count
----------------------------------------

Enumeration of CTCs and CECs in whole blood was performed by the CellSearch System according to manufacturer\'s instructions ([@bib7]; [@bib30]). An event is classified as a CTC or CEC when its morphological features are consistent with that of a cell and it exhibits the phenotype EpCAM+, CK+, DAPI+ and CD45- or CD146+, CD105+, DAPI+ and CD45-, respectively. Quantitative results were expressed as per 7.5 ml blood and per 4 ml blood for CTC and CEC, respectively.

To investigate drug-induced cell death throughout Sunitinib treatment, live and apoptotic CTCs were detected by integrating CTC assay with anti-M30 mAb, targeting a neoepitope disclosed by caspase cleavage at cytokeratin 18 in early apoptosis ([@bib29]); results are expressed as the total number of CTC and M30-positive CTC per 7.5 ml of blood.

Immunohistochemistry (IHC)
--------------------------

All enrolled patients who have undergone kidney surgery (radical nephrectomy or nephron-sparing surgery) or metastasis biopsy were included in the IHC study (34 patients) for EpCAM expression. The EpCAM expression in renal cancer is a critical issue, being reported between 15 and 40% of clear cell RCC samples depending on the study ([@bib33]; [@bib36]; [@bib17]). Details on immunostaining and controls are on-line provided as [Supplementary Data](#sup1){ref-type="supplementary-material"}. Only positive membranous immunostaining with anti-EpCAM (clone MOC-31; Cell Marque, Rocklin, CA, USA) was considered and semi-quantitatively scored in a four-tier scale that combined intensity (score-0, score-1, score-2 and score-3) and prevalence (%) of positive immunostaining. Results were grouped as following: negative=no stain; weak=score-1 in\<60%, or score-2 in\<30% of tumour cells; moderate=score-1 in ⩾60%, or score-2 in 30-80%, or score-3 in \<30% of tumour cells; strong=score-2 in ⩾80%, or score-3 in⩾30% of tumour cells (no 'strong\' cases were faced in the present series).

Statistical analysis
--------------------

Data were analyzed utilising the StatGraphics software (version 2.6), as previously reported ([@bib3]). The non-parametric Mann--Whitney or Wilcoxon tests were used to compare the quantitative variables. Frequencies were compared by Fisher\' exact test (two tails) or *χ*^2^ test with Yates\' correction where appropriate. Non-linear regression analysis was performed to assess the relationship between CTC and CEC levels.

The cumulative changes of live and apoptotic CTCs were expressed as previously described ([@bib29]) by the parameter ΔAUC: the detected numbers of M30-negative and M30-positive CTCs were separately plotted in relation to time and the area under the curve (AUC) of longitudinal graphs was calculated (by the trapezoidal rule) following a procedure which is commonly adopted to evaluate cumulative changes of serological tumour markers ([@bib9]). The difference between live and apoptotic CTC concentration-time area was calculated in all patients according to the following formula:

Progression-free survival (PFS) was measured as the time between the baseline CTC assessment (i.e., the initiation of treatment) and the documentation of first radiographic disease progression or death. Patients who were alive and progression-free at the time of analysis were censored by using the time between the baseline CTC assessment and their most recent follow-up evaluations.

The PFS between groups defined by ⩽0 or\>0 ΔAUC was compared with the Kaplan--Meier method, and differences were tested with the log-rank test.

Results
=======

CTC were detectable in the majority of mRCC patients
----------------------------------------------------

To test whether total and M30-positive CTC were detectable in mRCC patients, blood samples from 53 patients were tested at diagnosis before starting the therapy. The patient characteristics and the distribution of CTC number are shown in [Table 1](#tbl1){ref-type="table"}. Histology was obtained in 44 patients (83%): clear cell histotype was predominant (36 patients, 81.8%), following papillary-cell (3 patients, 6.8%), sarcomatoid type (2 patients, 4.5%) and other histotypes (3 patients, 6.8%).

Thirty-one (58.5%) mRCC patients had at least one CTC, 19 (35.8%) patients had two or more CTCs. Twenty-six (83.9%) CTCs-positive patients had one or more M30--positive CTCs. The number of CTCs and M30-positive CTCs ranged from 1 to 141 (median 2) and 0 to 67 (median 2) cells, respectively. The percentage of CTC-positive patients and total CTCs resembles the data previously reported at diagnosis in other metastatic tumours such as prostate (78% CTC-positive pts, median 9 cells) ([@bib8]), breast (65% CTC-positive patients, median 3 cells) ([@bib7]; [@bib16]; [@bib31]; [@bib25]) and colorectal cancer (47% CTC-positive patients, median 5 cells of those patients with ⩾2 CTCs) ([@bib1]; [@bib32]). The presence of CTCs and M30-positive CTCs at diagnosis was not associated with any specific clinicopathologic features with few exceptions ([Table 1](#tbl1){ref-type="table"}). The presence of CTCs at baseline demonstrated a trend with the detection of distant metastasis (lung, mediastinal LN, liver or bone, *P*=0.075; [Table 1](#tbl1){ref-type="table"}).

EpCAM expression can be acquired during disease progression
-----------------------------------------------------------

To detect CTC in follow-up study, obvious advantages of good sensitivity and reproducibility are offered by the automated technologies ([@bib2]), that mostly depend on the presence of EpCAM on the cell surface for capturing CTCs. To address this question in mRCC, histological sections were analyzed by IHC for EpCAM expression in 34 patients (64%) that had undergone kidney surgery, either primary tumour resection (17 cases) and metastasis biopsy (6 cases (3 lung, 1 bone, 1 SNC and 1 thyroid metastasis)) or both (11 cases). Appropriate positive, negative and inner controls are shown in [Supplementary Figure S1](#sup1){ref-type="supplementary-material"}, in [Supplementary data](#sup1){ref-type="supplementary-material"}. The data obtained by IHC was compared with CTC count.

Overall, 14 out of 34 patients (41.2%) expressed EpCAM in primary tumour, in metastasis or in both sites. As shown in [Figure 1A](#fig1){ref-type="fig"}, overall only minor changes were found in metastasis sections both as percentage of EpCAM-positive samples (from 32% to 41% of analyzed samples in primary *vs* secondary lesions, respectively, *P*=0.749) and as staining intensity (moderate grade expression from 33% to 43% of EpCAM-positive samples in primary *vs* secondary lesions, respectively, *P*=1). Conversely, higher percentage of EpCAM-positive samples was found by CellSearch analysis (*P*\<0.001): the great majority (85%) of the patients, which entered the IHC study, were CTC-positive, with 'zenith\' (i.e. the highest CTC no./7.5 ml during follow-up) values of CTCs comprised between 1 and 4 (69%), between 5 and 10 (17%) and more than 10 (14%).

In particular, for 11 patients CTC detection was performed at the time of metastasis biopsy, so that comparison can be performed by synchronous CTC detection and EpCAM expression in secondary lesions *vs* EpCAM expression in primary tumours ([Figure 1B--D](#fig1){ref-type="fig"}). Synchronous CTC and IHC analysis were performed before starting the treatment. As shown in [Table 2](#tbl2){ref-type="table"} the EpCAM-positive cases in the primary lesion (3 patients, weak expression) duplicate in secondary lesions (6 patients, 4 weak and 2 moderate expression; *P*=0.156). Remarkably, four of these six patients were negative in the primary tumour, suggesting *de novo* acquisition of EpCAM expression in metastasis ([Figure 1B--D](#fig1){ref-type="fig"} and [Supplementary Figure S2](#sup1){ref-type="supplementary-material"}). In seven of the seven patients (100%) that showed EpCAM-positive IHC (in primary or secondary lesions) at least one point during follow-up CTCs were also detected ([Table 2](#tbl2){ref-type="table"}, 'zenith\' CTC no.). Moreover, CTCs were further detected in three out of four patients (75%) that appeared EpCAM-negative both in primary and secondary lesions (two patients with lung and one with SNC metastasis); in these patients at the time of the synchronous CTCs detection bone metastasis (patient number 8 and 27 in [Table 2](#tbl2){ref-type="table"}) or multiple visceral metastasis (patient number 31 in [Table 2](#tbl2){ref-type="table"}) were also documented by imaging that were not included in IHC study. Overall, higher number of EpCAM-positive samples was found by CellSearch analysis (*P*=0.035).

Serial M30-integrated CTC assay during antiangiogenic treatment
---------------------------------------------------------------

To investigate whether the integrated test may predict therapeutic response in mRCC, CTC and M30-positive CTC were sequentially assessed under first-line Sunitinib treatment in 43 evaluable patients.

All patients had received the therapy schedule '4-2\' with a starting dose of 50 mg per day for 4 weeks, followed by a 2-week off-drug period. Sunitinib-dose reduction of 25% (37.5 mg) and 50% (25 mg) for grade 3--4 hematologic and non-hematologic toxicities was observed in 21 (48.8%) and 4 patients (9.3%), respectively.

Overall, median follow-up was 184 days (range 28 to 861 days). One case of complete response (CR), 5 cases of partial response (PR) and 20 cases of stable disease (SD) were observed, with median PFS of 258 days (range 40--524 days). Two cases of dead-of-disease (DOD) and 15 cases of progressive disease (PD) were observed, with median time-to-progression (TTP) of 112 days (range 28--861 days).

Lower baseline median number of total and M30-positive CTCs was weakly associated with the outcome of non-progressed (including CR, PR and SD) *vs* progressed (including DOD and PD) patient groups (0.5 CTCs and 0.0 M30+ *vs* 2.0 CTCs and 1.0 M30+, *P*=0.069 and 0.061, respectively; [Table 3](#tbl3){ref-type="table"}). Conversely, at the end of the first cycle no significant changes were measured in total and M30-positive CTCs number in either group ([Table 3](#tbl3){ref-type="table"}).

The presence of CTCs at baseline was not associated with the outcome: 5 of 18 CTC-negative and 12 of 25 CTC-positive patients belonged to the progressed group (*P*=0.219); however, in the CTC-positive group of patients that completed the second cycle of Sunitinib (21 cases), the presence of M30-negative CTCs at baseline was weakly associated with the poor outcome (6 progressed out of 7 (85.7%) *vs* 6 progressed out of 14 (42.9%) between live and apoptotic CTCs-positive patients, *P=*0.078)).

Analysis of the live/apoptotic CTC cumulative changes over the follow-up period
-------------------------------------------------------------------------------

Accurately assessing the cumulative changes of live/apoptotic CTCs number under chemotherapy have disclosed the predictive relevance of apoptotic CTCs in MBC ([@bib29]). To address this question in mRCC the observed variations under Sunitinib were expressed as reported ([@bib29]) by the parameter ΔAUC: the detected numbers of M30-negative (live) and M30-positive (apoptotic) CTCs were plotted in relation to time and the difference of the AUC of longitudinal graphs was calculated ([@bib29]).

The non-progressed group showed lower median values of ΔAUC compared with the progressed (−86.00 *vs* −5.50, *P*=0.010, [Table 3](#tbl3){ref-type="table"}), indicating that higher values of extra apoptotic CTCs over the follow-up period were associated with better outcome.

Moreover, categorising the patients for positive ΔAUC value (that is expression of extra live CTCs over the follow-up period) *vs* negative or 0 ΔAUC (that is expression of extra apoptotic CTC over the follow-up period or equal live/apoptotic CTC), we found that a positive ΔAUC was associated with progression (*P*=0.004, [Table 3](#tbl3){ref-type="table"}).

To assess the goodness of the 0 cutoff for the ΔAUC, 1000 distributions of size 500 were generated for non-progressed patients using bootstrap techniques. A 95% confidence interval (CI) was estimated for the probability of committing a first type error, that is the probability of classifying a patient as progressed (because ΔAUC\>0) when actually he is not. The 95% CI was (0; 92). Despite the small sample size of this data set, the analysis performed supports the choice of the 0 cutoff for discriminating between progressed and non-progressed patients.

The criterion of ΔAUC \>0 has sensitivity 42%, specificity 96%, positive predictive value 87% and negative predictive value 71% in predicting the patients who will undergo disease progression.

Shorter median PFS was observed for patients who had ΔAUC \>0 compared with ΔΔAUC ⩽0 patients (112 *vs* 462 days; *P*=0.030; [Figure 2](#fig2){ref-type="fig"}).

At progression, 11 of 17 progressed patients showed distant metastasis that were associated with higher median ΔAUC values than in the locally recurring patients (34.50 *vs* −24.00; *P=*0.050; [Table 3](#tbl3){ref-type="table"}); categorising the progressed patients for ΔAUC \>0 *vs* ΔAUC ⩽0, positive ΔAUC was associated with distant metastasis (*P*=0.017, [Table 3](#tbl3){ref-type="table"}). Distant metastases were not associated with shorter TTP (*P*=0.802).

Synchronous CEC and CTC changes during antiangiogenic treatment
---------------------------------------------------------------

Under antiangiogenic treatment combined with chemotherapy CTC changes were not reported as an early surrogate marker of survival ([@bib4]) whereas significant decrease in CEC levels was associated with tumour progression in MBC. To investigate this issue in mRCC, CEC and CTC levels were sequentially assessed in 30 patients under first-line Sunitinib treatment.

Comparable baseline CEC values were measured both in patients and healthy controls (39 vs 45; *P*=0.845) as well as in non-progressed and progressed patients (34 *vs* 45; *P*=0.867, [Table 4](#tbl4){ref-type="table"}). Conversely, at the end of the first cycle increasing CEC levels were measured that appeared weakly associated with outcome ([Table 4](#tbl4){ref-type="table"}).

To establish a combinatory model using both CTCs and CEC levels, synchronous determinations were plotted in relation to time ([Figure 3](#fig3){ref-type="fig"}). The CTC and CEC changes were associated according to waveform model of regression analysis (*R*^2^=0.67, *P=*0.05, [Figure 3A](#fig3){ref-type="fig"}). The relationship between CTC and CEC levels were stronger in the non-progressed patients (*R*^2^=0.90, *P=*0.05) than in progressed patients (*R*^2^=0.38, *P=*0.05, [Figure 3C](#fig3){ref-type="fig"}).

Discussion
==========

At present, design of clinical trials, interpretation of outcome data and finally clinical managing of mRCC patients are based on predictive models of risk including a series of prognostic factors (time to start of therapy, serum LDH and Calcium levels, anemia and low performance status) ([@bib24]). Conversely, very few papers address the discovery of new biomarkers of treatment efficacy in these patients ([@bib28]).

In the current study, we evaluated the clinical relevance of total and M30-positive CTCs in patients with mRCC during first-line Sunitinib treatment, obtaining new insight about the role and mechanism of CTCs in mRCC and in tumour evasion to antiangiogenic treatment.

Interestingly, 58.5% mRCC patients had at least one CTC and 35.8% patients had two or more CTCs. Considering the low level of EpCAM expression reported in the predominant clear cell histotype RCC, this finding is not assumed. Indeed, by IHC analysis EpCAM positivity was reported in 15 (33%) of 45 clear cell RCC ([@bib17]), whereas using a dichotomised criteria for positive and negative groups (frequencies of staining of ⩾5% and \<5%, respectively), in a 318 case series Seligson and coworkers reported that 41% of clear cell RCC patients were EpCAM-positive ([@bib33]).

We demonstrated that 41.2% of mRCC (CC hystotype 81.8%) expressed EpCAM in the primary tumour and/or secondary lesions; the great majority of them had CTCs positive, but cells were also detected in cases classified as EpCAM-negative histology. Technical hitches may explain the differing results obtained by IHC and CellSearch analysis. IHC is the most commonly used method for evaluating antigen expression on paraffin-embedded sections of solid tumours. However, this technique depends on the various fixation protocols, assay methods, antibodies, and scoring systems used in different laboratories that altogether limit the value of IHC in measuring antigen expression at single-cell levels. Provided that it uses a robust method, the heterogeneous expression of a given antigen may be potentially more evaluable in tumour cells in peripheral blood.

Nevertheless, we find that the frequency of EpCAM-positive metastasis was higher compared with primary lesions, contrasting previously reported IHC data that metastatic lesions lack EpCAM expression ([@bib36]). Limited inter-laboratory IHC reproducibility and tumour heterogeneity may explain our findings, but an alternative intriguing argument is that the enrichment of EpCAM-positive cancer cells may have a role for the invasive phenotype ([@bib18]). Indeed, the biological role of EpCAM in carcinogenesis is controversial: loss of membranous EpCAM was reported to contribute to increased migratory potential ([@bib11]); conversely, abrogating E-cadherin-mediated cell--cell adhesion EpCAM expression might promote metastasis ([@bib37]). Moreover, EpCAM overexpression has been associated with both decreased and increased survival of patients ([@bib34]). However, EpCAM is also known to be highly expressed in cancer stem cells ([@bib35]) in breast, colorectal and pancreatic tumours.

Our study has few limitations that may limit the value of these observations. For example, because of the small cohort of patients, the threshold value of baseline CTCs associated with poor outcome cannot be determined ([@bib7]), and the prognostic significance of lower than cutoff CTC number cannot be evaluated here. The major finding of the study is provided by the first clear evidence that the amount of live CTCs is a more sensitive marker for rating pharmacodynamic effects compared with total CTCs counts, also when the threshold of poor outcome remains to be defined. The changes in the M30-negative/positive CTCs balance disclose an active disease, as documented by consistent radiological findings, and ΔAUC\>0 (i.e., persistence of live tumour cells under therapy) is associated with progression in individual patient.

We believe that the lack of M30 expression represents in principle a phenotypic (and biologic) property, which should be necessary to metastatic process ([@bib2]). Furthermore, induction of tumour cell death is regarded as a unique biomarker of treatment efficacy. Hence, through phenotyping CTC for vitality under any treatment and accurately assessing their changes during follow-up it should be possible to stratify CTC on 'biologic\' rather than 'statistic\' basis, and dichotomise tumour response by the persistence or the lack of live cells.

Sunitinib has been established as a novel standard for first-line therapy, providing a new frontier in the management of metastatic RCC. However, although antitumour effects and survival benefit are often evident, relapse to progressive tumour growth typically ensues, reflecting multiple mechanisms of adaptation to antiangiogenic therapies ([@bib15]); indeed, under antiangiogenic pressure distant and accelerated metastasis have been reported in preclinical models ([@bib10]; [@bib23]). In the current study we showed that 64.7% of the progressed patients relapse with distant metastasis, which were associated with ΔAUC\>0 but not with shorter TTP. This finding not only indirectly proves the metastatic potential of the M30-negative CTC, but further underlines the role of antitumour cells targeting for preventing tumour evasion *in vivo*, as suggested by the observation that positive ΔAUC predicts poor outcome better than CEC changes after the first cycle of treatment. Nevertheless, the CTC changes closely mirrored CEC fluctuations measured under the discontinuous schedule of Sunitinib. A rapid increase of the CEC number as fast as the first cycle was associated with CTC decrease in non-progressed patients, whereas a delayed response of CECs was related to higher CTC values in the progressed group, suggesting that the antiendothelial targeting and the antitumour cells effects are strictly linked *in vivo*.

In conclusion, our data indicate that serial total and apoptotic CTC enumeration in conjunction with standard radiographic imaging improves our ability to accurately assess the treatment benefit for individual mRCC patients under Sunitinib treatment. Prospectively, by gaining more knowledge about mechanisms of tumour adaptation to antiangiogenic treatment the total and apoptotic CTCs enumeration in conjunction with the CEC count might guide the choice of combination or sequences of different agents (including tyrosine kinase inhibitors, mAbs and many more antiangiogenic compounds) for modulating tumour evasion.
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![EpCAM expression in mRCC primary tumours, metastasis and CTC. (**A**) EpCAM expression was analysed by IHC in primary tumours (T, *n=28*) and metastasis (M, *n=17*) obtained from 34 patients, for comparing IHC data with CTC results. The white bars represent the EpCAM-negative IHC in T (19 out of 28) and in M (10 out of 17) and patients that were CTC-negative by CellSearch assay (5 out of 34). The light brown bars represent weak staining in T (6 out of 9) and M (4 out of 7); the dark brown bars represent Moderate staining in T (3 out of 9) and M (3 out of 7). The light blue bar symbolises patients that had 1--4 CTC (20 out of 29), the dark blue bar symbolises patients that had 5--10 CTC (5 out of 29), the deep blue bar symbolises patients that had more than 10 CTC (4 out of 29). (**B**) The EpCAM staining profile is consistent in secondary lesions and synchronous CTC detection; one representative case of 4 is shown. The primary renal lesion (patient number 58) does not feature any EpCAM immunostaining (Original magnification 20X). (**C**) Characteristic EpCAM membranous immunoreaction appears in the tumour biopsy obtained from the surrenalic metastasis (patient number 58). (Original magnification × 20). (**D**) Analysis of three rare cells in baseline blood sample of patient number 58 using an Analyzer II device (Veridex, Raritan, NJ, USA). Horizontally, the photos show the same cell stained for the combination (Comp) of CK (green) and DAPI (violet); CK PE only; DAPI only; CD45 APC only; and M30 FITC only. The red squares indicate positively stained cells: events \#1 and \#7 are live CTC, exhibiting strong and irregular CK staining, respectively; in the photo \#19 based on M30 staining profile (sufficient signal relative to background) the event on the right is classified as apoptotic CTC; the event on the left is a leukocyte (CD45-positive).](bjc2012388f1){#fig1}

![Progression-free survival (PFS) for patients with negative or equal 0 *vs* positive ΔAUC. Progression-free survival was measured as the time between the baseline CTC assessment and documentation of first radiographic evidence of disease progression or death. The ΔAUC criterion represents the difference between live and apoptotic CTC concentration-time area and was calculated in all patients according to the following formula:](bjc2012388f2){#fig2}

![CEC and CTC changes in mRCC patients under Sunitinib. (**A**) CEC and CTC values (mean +1 s.d., white and black symbols, respectively) synchronously determined in 30 mRCC patients receiving Sunitinib treatment are plotted in relation to time. (**B**) The bars represent the number of CEC and CTC samples (white and black symbols, respectively) collected at each time point. (**C**) CEC and CTC longitudinal graphs (white and black symbols, respectively) are separately plotted for non-progressed and progressed patients (○ and ∇ symbols, respectively). Time points with *n* ⩾14 were showed.](bjc2012388f3){#fig3}

###### Patients and primary tumour characteristics by CTC and M30-positive CTC detection at baseline

                                                 ***n***   **CTC negative**   **CTC positive**   ***P*** **value**[a](#t1-fn2){ref-type="fn"}   **M30+**   ***P*** **value**[b](#t1-fn3){ref-type="fn"}   **M30+%**   ***P*** **value**[c](#t1-fn4){ref-type="fn"}                
  ---------------------------------------------- --------- ------------------ ------------------ ---------------------------------------------- ---------- ---------------------------------------------- ----------- ---------------------------------------------- ------ ----- -------
  All subjects                                   53        22                 41.5%              31                                             58.5%                                                     26          84%                                                   73     
  *Age at diagnosis*                                                                                                                                                                                                                                                              
   ⩽35                                           3         2                                     1                                                         0.42                                           1                                                          0.14   67     
   36--50                                        5         1                                     4                                                                                                        2                                                                 42     
   ⩾51                                           45        19                                    26                                                                                                       23                                                                78     
                                                                                                                                                                                                                                                                                   
  *Sex*                                                                                                                                                                                                                                                                           
   M                                             41        17                                    24                                             \*         1                                              20          \*                                             1      70    1
   F                                             12        5                                     7                                                                                                        6                                                                 83     
                                                                                                                                                                                                                                                                                   
  *T (*n*=30)*                                                                                                                                                                                                                                                                    
   T1                                            8         3                                     5                                                         0.08                                           5                                                          0.29   93    0.30
   T2                                            5         5                                     0                                                                                                        ---                                                               ---    
   T3                                            16        7                                     9                                                                                                        6                                                                 55     
   T4                                            1         0                                     1                                                                                                        1                                                                 100    
                                                                                                                                                                                                                                                                                   
  *N (*n*=30)*                                                                                                                                                                                                                                                                    
   N0                                            11        7                                     4                                              \*         0.45                                           4           \*                                             0.73   92    1
   N1--N3                                        19        8                                     11                                                                                                       8                                                                 63     
                                                                                                                                                                                                                                                                                   
  *M (*n*=25)*                                                                                                                                                                                                                                                                    
   M0                                            6         3                                     3                                                         0.63                                           2                                                          0.36   56    0.053
   M1                                            7         2                                     5                                                                                                        4                                                                 63     
   Mx                                            12        6                                     6                                                                                                        6                                                                 100    
                                                                                                                                                                                                                                                                                   
  *Fuhrman grading (*n*=28)*                                                                                                                                                                                                                                                      
   G1                                            1         0                                     1                                                         0.23                                           1                                                          0.74   100   0.24
   G2                                            12        8                                     4                                                                                                        3                                                                 75     
   G3                                            13        7                                     6                                                                                                        5                                                                 78     
   G4                                            2         0                                     2                                                                                                        1                                                                 34     
                                                                                                                                                                                                                                                                                   
  *Histology (*n*=44)*                                                                                                                                                                                                                                                            
   CC carcinoma                                  36        16                                    20                                             \*         1                                              16          \*                                             1      71    0.16
   Others                                        8         3                                     5                                                                                                        4                                                                 53     
                                                                                                                                                                                                                                                                                   
  *Sites of metastasis at blood draw (*n*=48)*                                                                                                                                                                                                                                    
   Contralateral kidney                          4         4                                     0                                                         0.075                                          ---                                                               ---    
   Lung, mediastinal LN or liver                 37        15                                    22                                                                                                       17          \*                                             0.80   67    1
   Bone                                          7         3                                     4                                                                                                        4                                                                 92     

  ------------------------------------------------------------------------ ------ ------ ------ ------ ------ ------ -----
  *Distribution of CTC and M30-positive CTC in RCC patients at baseline*                                             
   CTC no./7.5 ml                                                           \<1     ⩾1     ⩾2     ⩾3     ⩾4     ⩾5    ⩾10
   No. of patients                                                           22     31     19     14     8      5      2
   Percent (%)                                                              41.5   58.5   35.8   26.4   15.1   9.4    3.8
   M30-positive no./7.5 ml                                                  \<1     ⩾1     ⩾2     ⩾3     ⩾4     ⩾5    ⩾10
   No. of patients                                                           5      26     16     10     6      4      1
   Percent (%)                                                              16.1   83.9   51.6   32.3   19.4   12.9   3.2
  ------------------------------------------------------------------------ ------ ------ ------ ------ ------ ------ -----

Abbreviations: CTC=circulating tumour cells; LN=lymph node; RCC=renal cell carcinoma.

CTC detection; *χ*^2^ test or Fisher\'s exact(\*) test were employed where appropriate.

M30-positive CTC detection; *χ*^2^ test or Fisher\'s exact (\*) test were employed where appropriate.

Percentage of M30-positive CTC; median test.

###### EpCAM expression and CTC detection in mRCC

  ***\#***   **Age**    **Sex**  **Histology**                **T**   **N**   **M**   **Furhman grading**   **Source for IHC study**                         **EpCAM in primary** **tumour (score)**   **EpCAM in metastasis**[a](#t2-fn2){ref-type="fn"} **(score)**  **CTC no.**[b](#t2-fn3){ref-type="fn"}   **'Zenith\'**[c](#t2-fn4){ref-type="fn"} **CTC no.**
  ---------- --------- --------- ---------------------------- ------- ------- ------- --------------------- ----------------------------------------------- ----------------------------------------- ---------------------------------------------------------------- ---------------------------------------- ------------------------------------------------------
  2          34            M     Type 2 papillary Carcinoma   3b      0       1       3                     K+lung metastasis                                                  Neg                                               Pos (weak)                            3                                        14
  27         69            M     CC carcinoma                 3a      x       x       3                     K+lung metastasis[d](#t2-fn5){ref-type="fn"}                       Neg                                                  Neg                                2                                        3
  31         70            F     CC carcinoma                 1a      0       x       1                     K+CNS metastasis[e](#t2-fn6){ref-type="fn"}                        Neg                                                  Neg                                2                                        2
  37         77            F     CC carcinoma                 2       0       x       2                     K+thyroid and cutaneous metastasis                             Pos (weak)                                               Neg                                \<1                                      12
  51         88            M     CC carcinoma                 1b      x       x       2                     K+lung metastasis                                                  Neg                                               Pos (weak)                            1                                        2
  54         48            F     CC carcinoma                 ---     ---     ---     4                     K+hepatic metastasis                                           Pos (weak)                                            Pos (weak)                            1                                        1
  55         74            M     CC carcinoma                 ---     ---     ---     3                     K+lung metastasis                                              Pos (weak)                                          Pos (moderate)                          \<1                                      2
  58         68            M     CC carcinoma                 3a      0       x       2                     K+surrenalic metastasis                                            Neg                                             Pos (moderate)                          1                                        1
  8          57            M     CC carcinoma                 x       x       1       2                     K+lung metastasis [d](#t2-fn5){ref-type="fn"}                      Neg                                                  Neg                                5                                        16
  42         64            M     CC carcinoma                 ---     ---     ---     ---                   K+metastasis                                                       Neg                                               Pos (weak)                            1                                        1
  19         63            M     *---*                        ---     ---     ---     ---                   K+surrenalic metastasis                                            Neg                                                  Neg                                \<1                                      \<1

Abbreviations: CC=clear cell; CNS=central nervous system; CTC=circulating tumour cells; IHC=immunohistochemistry; mRCC=metastatic renal cell canrcinoma.

Metastasis biopsy and CTC detection were synchronously performed before starting the treatment.

CTC no./7.5 ml at the first blood draw.

The highest CTC no./7.5 ml during the follow-up.

Bone metastasis were documented by imaging that were not biopsied.

Multiple visceral metastatic lesions were documented by imaging that were not biopsied.

###### Outcome according to CTC and M30-positive CTC count and ΔAUC

                                                   **n**   **CTC**[a](#t3-fn2){ref-type="fn"}   ***P*** **value**[b](#t3-fn3){ref-type="fn"}   **1° Cycle CTC**[a](#t3-fn2){ref-type="fn"}   ***P*** **value**[c](#t3-fn4){ref-type="fn"}   **M30+**[d](#t3-fn5){ref-type="fn"}   ***P*** **value[b](#t3-fn3){ref-type="fn"}**   **1° Cycle M30+**[d](#t3-fn5){ref-type="fn"}   ***P*** **value**[c](#t3-fn4){ref-type="fn"}   Δ**AUC**[e](#t3-fn6){ref-type="fn"}   ***P*** **value**[b](#t3-fn3){ref-type="fn"}   Δ**AUC** ⩽**0**   Δ**AUC \>0**   ***P*** **value[f](#t3-fn7){ref-type="fn"}**   **TTP (days)**[g](#t3-fn8){ref-type="fn"}   ***P*** **value**[b](#t3-fn3){ref-type="fn"}
  ------------------------------------------------ ------- ------------------------------------ ---------------------------------------------- --------------------------------------------- ---------------------------------------------- ------------------------------------- ---------------------------------------------- ---------------------------------------------- ---------------------------------------------- ------------------------------------- ---------------------------------------------- ----------------- -------------- ---------------------------------------------- ------------------------------------------- ----------------------------------------------
  Non-progressed                                   26      0.5                                  0.069                                          0.5                                           0.284                                          0.0                                   0.061                                          0.5                                            0.304                                          −86.00                                0.010                                                                                                                                                                       
  Progressed                                       17      2.0                                                                                 1.0                                           0.426                                          1.0                                                                                  1.0                                            0.791                                          −5.50                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  *Outcome according to categorised* Δ*AUC*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
   Non-progressed                                  26                                                                                                                                                                                                                                                                                                                                                                                                                                                               25                1              *0.004*                                                                                     
   Progressed                                      17                                                                                                                                                                                                                                                                                                                                                                                                                                                               10                7                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  *Sites of disease relapse according to* Δ*AUC*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
   Locally heightened invasion                     6                                                                                                                                                                                                                                                                                                                                                                           −24.00                                *0.050*                                        6                 0              *0.017*                                        131                                         *0.802*
   Distant metastasis                              11                                                                                                                                                                                                                                                                                                                                                                          34.50                                                                                4                 7                                                             107                                          

Abbreviations: AUC=area under the curve; CTC=circulating tumour cells.

Median values of total CTC/7.5 ml.

Non-progressed *vs* progressed, locally *vs* Distant comparison by Mann--Whitney test.

Before and after 1° cycle comparison by Wilcoxon paired test.

Median values of M30-positive CTC/7.5 ml.

Live/apoptotic CTC balance over the follow-up period.

Fisher\'s exact test (two tail).

Median number of days to progression. *P*-value of dichotomized data are provided in italic.

###### Outcome according to CEC

                   **n**   **CEC[a](#t4-fn2){ref-type="fn"}**   ***P*** **value[b](#t4-fn3){ref-type="fn"}**   **1° Cycle CEC[a](#t4-fn2){ref-type="fn"}**   ***P*** **value[b](#t4-fn3){ref-type="fn"}**   ***P*** **value**[c](#t4-fn4){ref-type="fn"}
  ---------------- ------- ------------------------------------ ---------------------------------------------- --------------------------------------------- ---------------------------------------------- ----------------------------------------------
  Non-progressed   15      34                                   0.867                                          63.5                                          0.751                                          0.057
  Progressed       13      45                                                                                  87.0                                                                                         0.155

Abbreviation: CEC=circulating endothelial cell.

Median values of CEC/4 ml.

Non-progressed *vs* progressed comparison by Mann--Whitney test.

Before and after 1° cycle comparison by Mann--Whitney test.
